Clinical trials: Dalteparin
Pulmonary Embolism
SR34006 Compared to Vitamin K Antagonist (VKA) in the Treatment of Pulmonary Embolism
Patients who have a pulmonary embolism (blood clot in the lung) will be treated in this study. The purpose of the study is to compare the safety and effectiveness of a new injectable anticoagulant (blood-thinning) drug, SR34006…
- Trial name
- NCT00062803
- Testing
- SR34006, (LMW)heparin, Warfarin VKA
- Where
- 93 sites in United States, Argentina and 18 more
- Sponsor
- Sanofi
Leg Injuries, Winter Sport Resorts
Evaluation of the Prevention of Thromboembolic Disease in Patients With a Lower Limb Trauma, Non Surgical, in Winter Sports Resort
The purpose of this study is to evaluate the impact of thromboembolic diseases and heparin complications in patients with a lower limb trauma supported by physicians of mountain.
- Conditions
- Leg Injuries, Winter Sport Resorts, Outpatients
- Trial name
- M2M-Thrombose (NCT01303523)
- Where
- 28 sites in France
- Volunteers
- 1,627 people
- Sponsor
- Floralis
Persistent Nonvalvular Atrial Fibrillation
Atrial Fibrillation Feasibility Certoparin Trial - AFFECT
This trial is designed to provide data about feasibility and safety of short-term treatment with the low-molecular-weight heparin certoparin in patients with persistent nonvalvular atrial fibrillation
- Trial name
- NCT00171769
- Testing
- Certoparin
- Where
- 2 sites in United States, Germany
- Volunteers
- 200 people
- Sponsor
- Novartis
Thrombosis, Hip Replacement
A Study of DU-176b in Preventing Blood Clots After Hip Replacement Surgery
This study is to assess if DU176b is effective in prevention of blood clots following hip replacement surgery. The duration is 7-10 days of treatment and 30 and 60 day follow-up visits.
- Trial name
- NCT00398216
- Testing
- DU176b - action is the prevention of venous thromboembolism by the use of a Factor Xa inhibitor
- Where
- 29 sites in United States, Canada and 5 more
- Volunteers
- 903 people
- Sponsor
- Daiichi Sankyo
Embolism
Efficacy and Safety of Low-molecular Weight Heparin for Thromboprophylaxis in Acutely Ill Medical Patients
Acutely ill immobilized patients are at a high risk for thromboembolic events including deep venous thrombosis or pulmonary embolism.
- Trial name
- NCT00311753
- Testing
- Certoparin, Heparin
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 342 people
- Sponsor
- Novartis Pharmaceuticals
Medical Prevention Therapy
Canadian Outpatient VTE Management Registry
Primary Objective: To obtain prospective, clinical practice-based data on how symptomatic VTE is managed with low molecular weight heparin (LMWH) enoxaparin in Canadian outpatient settings.
- Trial name
- RECOVERY (NCT01133002)
- Where
- Canada
- Volunteers
- 915 people
- Sponsor
- Sanofi
Healthy
Bioequivalence Study of a Generic Enoxaparin Sodium to Clexane® After Single Subcutaneous Dose in Healthy Human Subjects
This is a single-dose, randomized, double-blind, two-period, two-treatment, two-sequence, crossover, balanced, pharmacodynamic (PD) study with 7 days wash-out period.
- Trial name
- NCT05265676
- Testing
- Enoxaparin Sodium (Venus Remedies Limited), Enoxaparin Sodium (Sanofi)
- Where
- India
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Venus Remedies Limited
Healthy
Study of Pharmacodynamic Equivalence of Enoxaparin Rovi to Clexane®, in Healthy Volunteers
To demonstrate the pharmacodynamic (PD) equivalence of enoxaparin Rovi (100 mg/mL) 100-mg SC injection to Clexane® (100 mg/mL) 100-mg SC injection in healthy volunteers.
- Trial name
- NCT03363477
- Testing
- Enoxaparin, Clexane
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Rovi Pharmaceuticals Laboratories
Thrombosis, Venous
A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing Surgery
The purpose of this study is to evaluate the efficacy and safety of fondaparinux in comparison with a heparin (nadroparin) in preventing deep vein thrombosis (blood clots in the leg veins), whether symptomatic or detected by…
- Trial name
- FONDACAST (NCT00843492)
- Testing
- Fondaparinux sodium, Nadroparin
- Where
- 122 sites in France, Germany and 4 more
- Volunteers
- 1,351 people
- Sponsor
- GlaxoSmithKline
Deep-Vein Thrombosis
Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study
The purpose of this clinical research study is to assess efficacy and safety of 3 doses of apixaban 5 mg twice a day, 10 mg twice a day and 20 mg once daily versus conventional treatment with low molecular weight heparin or…
- Trial name
- NCT00252005
- Testing
- Apixaban
- Where
- 72 sites in United States, Australia and 9 more
- Volunteers
- 520 people
- Sponsor
- Bristol-Myers Squibb
Percutaneous Coronary Intervention, Coronary Artery Disease (CAD)
Reversal of Heparin in Patients Undergoing Percutaneous Coronary Intervention (PCI)
The study investigates the safety and efficacy of PMX-60056 for the Reversal of Heparin in Patients Undergoing Percutaneous Coronary Intervention (PCI)
- Conditions
- Percutaneous Coronary Intervention, Coronary Artery Disease (CAD), Angioplasty
- Trial name
- NCT01312935
- Testing
- PMX-60056
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- PolyMedix, Inc.
Cancer, Deep Vein Thrombosis
Study on Thrombosis Therapy in German Cancer Patients
The study aims to document the flow of German patients with cancer and acute deep vein thrombosis from first visit to diagnosis and treatment, the applied diagnostic procedures, and therapy modalities.
- Conditions
- Cancer, Deep Vein Thrombosis, Pulmonary Embolism
- Trial name
- NCT01559883
- Testing
- no intervention is being made
- Where
- Germany
- Volunteers
- 76 people
- Sponsor
- LEO Pharma
Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT)
Cancer Venous Thromboembolism (VTE)
The primary objective is to demonstrate the non-inferiority of edoxaban (preceded by a short course of LMWH) compared with dalteparin for the prevention of the combined outcome of recurrent venous thromboembolism (VTE) or major…
- Conditions
- Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Cancer
- Trial name
- NCT02073682
- Testing
- Edoxaban, Dalteparin, Low molecular weight heparin
- Where
- 9 sites in United States, Belgium and 4 more
- Volunteers
- 1,046 people
- Sponsor
- Daiichi Sankyo
Acute Ischemic Stroke
PREVAIL: PREvention of VTE After Acute Ischemic Stroke With LMWH Enoxaparin ( - VTE: Venous Thromboembolism - LMWH: Low Molecular Weight Heparin)
Primary objective: To demonstrate superiority of enoxaparin 40 mg sc qd in the prevention of VTE compared to UFH (unfractionated heparin) 5000 U sc q12 hours given for 10 ± 4 days following acute ischemic stroke.
- Trial name
- NCT00077805
- Testing
- Enoxaparin sodium
- Where
- 15 sites in United States, Australia and 13 more
- Sponsor
- Sanofi
Venous Thromboembolism, Deep Venous Thrombosis
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
This is a Phase 3, multicenter, open-label, blinded endpoint study to evaluate the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal…
- Conditions
- Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
- Trial name
- MAGNOLIA (NCT05171075)
- Testing
- Abelacimab, Dalteparin
- Where
- 117 sites in United States, Australia and 18 more
- Volunteers
- 417 people
- Sponsor
- Anthos Therapeutics, Inc.
Diabetic Foot Ulcer
The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients (A6301086)
The primary objective of this 6 month open-label extension trial is to evaluate long-term safety and tolerability of dalteparin in treatment of chronic neuroischaemic foot ulcers in diabetic patients with peripheral arterial…
- Trial name
- NCT00765063
- Testing
- Fragmin
- Where
- 27 sites in Austria, Belgium and 12 more
- Volunteers
- 62 people
- Sponsor
- Pfizer
Patients Receiving Rivaroxaban Treatment
Validation of Rivaroxaban Assay for US Registration
The objective of the study is to demonstrate the performances of the STA® - Rivaroxaban Calibrator and STA® - Rivaroxaban Control in combination with the STA® - Liquid Anti-Xa to determine the quantity of rivaroxaban in plasma…
- Trial name
- NCT02333929
- Testing
- STA- Rivaroxaban Calibrator&Control
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Diagnostica Stago
Pneumonia
Integrilin and Ilomedin in Combination in Comparison to Standard Treatment in Severe Pneumonia Patients With Severe Sepsis
This is an investigator sponsored double-blinded, multinational, multi center, randomized (2:1 active:placebo), placebo-controlled, phase IIa trial in severe pneumonia patients with severe sepsis or septic shock, investigating…
- Trial name
- NCT01532544
- Testing
- Ilomedin and Integrilin, low molecular weight heparin.
- Where
- 4 sites in Denmark, Finland
- Volunteers
- 5 people
- Sponsor
- Thrombologic ApS
Venous Thromboembolism
An Observational Study On The Safety And Tolerability Of Prolonged Thrombosis Prophylaxis With Fragmin®
The objective of this study is to observe the safety, tolerability, and compliance in the use of Fragmin® for prolonged thromboprophylaxis in post-surgery high-risk orthopedic patients.
- Trial name
- NCT01046903
- Testing
- Fragmin® (Dalteparin Sodium)
- Volunteers
- 503 people
- Sponsor
- Pfizer
Coagulation Disorder
Effects of VMX-C001 on the Anticoagulant Effect of Different Forms of Heparin
A single centre, open-label study to assess the effects of VMX-C001 in combination with an oral FXa DOAC on the efficacy of Unfractionated Heparin (UFH) and of VMX-C001 alone on the efficacy of Low Molecular Weight Heparin (LMWH)…
- Trial name
- NCT06517563
- Testing
- VMX-C001, Rivaroxaban, UFH
- Where
- Netherlands
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- VarmX B.V.